When given with rilpivirine for HIV-1 treatment, the dose of Descovy is 200/25 mg once daily. Coadministration of rilpivirine (25 mg once daily) and tenofovir alafenamide (25 mg once daily) had no effect on the AUC and Cmax of tenofovir alafenamide, nor on the AUC, Cmax and Cmin of rilpivirine.

Based on drug interaction studies conducted with the components of Descovy, no clinically significant drug interactions have been either observed or are expected when Descovy is combined with rilpivirine. Coadministration of rilpivirine (25 mg once daily) and tenofovir alafenamide (25 mg once daily) was studied in 17 subjects. Tenofovir alafenamide Cmax and AUC both increased by 1%; rilpivirine Cmax decreased by 7%, but AUC and Cmin increased by 1% and 13%.